Latest Content

Hernexeos led to high response rates and disease control in HER2-mutant NSCLC, including patients with brain metastases, with manageable safety.

I struggle sometimes, wondering, “Why me?” and “Why testicular cancer?” Was God telling me something? Maybe to slow down and let him take control. So, I try my best to let go.

Amanda discusses the hidden challenges of chronic GVHD and how advocacy and storytelling help her support others facing similar struggles.

Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer worsening compared with Tagrisso alone.

A study found microplastics in prostate tumors, with higher levels in cancer tissue, prompting further research into potential links and health effects.

So many friends I have met along the way wanted so badly to live and they weren't able to. They didn't lose and I didn't win. We all walked through something really hard and got different outcomes.

In the phase 3 ATHENA-MONO trial, 5-year data show Rubraca helped delay cancer worsening in advanced ovarian cancer vs placebo.

A living liver donor shares recovery challenges, emotional rewards and advice for those considering donation to help save a life.

KRAS G12d-targeted protein degrader setidegrasib demonstrated antitumor activity and a manageable safety profile in patients with KRAS G12d-mutant non–small cell lung cancer.

Nurse practitioner Bridget Hopkins discusses her metastatic breast cancer diagnosis, the role of clinical empathy and finding hope in stage 4 care.

In the last month, I had a revelation about my illness.

FDA approved Lifyorli plus Abraxane, improving survival in platinum-resistant ovarian, fallopian tube and peritoneal cancers.

Five-year ICESECRET data show high recurrence-free rates with cryoablation for small kidney tumors, supporting a minimally invasive treatment option.